Rationale Dopamine D 2 -like agonists maintain responding when substituted for cocaine in laboratory animals. However, these effects appear to be mediated by an interaction with stimuli that were previously paired with cocaine reinforcement (CS). Objectives To evaluate the extent to which the pramipexolemaintained and pramipexole-induced responding are influenced by cocaine-paired stimuli. Methods Rats were trained to nosepoke for cocaine under fixed ratio 1 (FR1) or progressive ratio (PR) schedules of reinforcement. In FR1-trained rats, pramipexole was substituted for cocaine with injections either paired with CSs, or delivered in their absence. The capacity of experimenteradministered pramipexole to induce FR1 and PR responding for CS presentation was evaluated. The effects of altering stimulus conditions, as well as pretreatments with D 2 -(L-741,626) and D 3 -preferring (PG01037) antagonists on pramipexole-induced PR responding were also evaluated. Results When substituted for cocaine, pramipexole maintained responding at high rates when injections were paired with CSs, but low rates when CSs were omitted. Similarly, experimenter-administered pramipexole induced dosedependent increases in FR1 or PR responding, with high rates of responding observed when the CS was presented, and low rates of responding when CS presentation was omitted. D 2 and D 3 antagonists differentially affected pramipexoleinduced PR responding, with L-741,626 and PG01037 producing rightward, and downward shifts in the doseresponse curve for CS-maintained responding, respectively. Conclusions These data indicate that pramipexole is capable of enhancing the reinforcing effectiveness of conditioned stimuli, and raise the possibility that similar mechanisms are responsible for the increased occurrence of impulse control disorders in patients being treated with pramipexole.
Introduction
Dopamine D 2 and D 3 receptors are thought to play important roles in drug-abuse-related and compulsive behaviors (e.g., Everitt et al. 2008; Heidbreder et al. 2005; Heidbreder and Newman 2010; Newman et al. 2005) . For instance, positron emission tomography (PET) studies in humans, monkeys, and rats suggest that lower levels of striatal D 2 -like receptor availability are correlated with both the positive subjective (Volkow et al. 1999 ) and reinforcing effects (Morgan et al. 2002) of psychostimulants, such as cocaine, as well as with increased measures of impulsivity which may predispose individuals to abuse cocaine (Dalley et al. 2007 ). In addition D 2 -like agonists have been shown to reinstate previously extinguished responding for cocaine (De Vries et al. 1999 Self et al. 1996) , possess some cocaine-like discriminative stimulus effects (Barrett et al. 2001; Terry et al. 1994) , and maintain responding at relatively high rates when substituted for cocaine in monkeys, rats, and mice (Caine and Koob 1993; Caine et al. 2002; Woolverton et al. 1984) . Although these findings suggest that D 2 and D 3 receptors mediate, at least partially, the subjective and reinforcing effects of cocaine, D 2 -like agonists generally fail to produce cocaine-like discriminative stimulus effects in humans (Haney et al. 1998; Kumor et al. 1989) , and are rarely abused (O'Sullivan et al. 2009 ). In fact, at clinically active doses pramipexole has been reported to increase sedation and nausea, and decrease positive mood and "like drug" effects (Hamidovic et al. 2008) , again suggesting that a disconnect exists between preclinical laboratory animal models that are generally very good at predicting the potential for abuse in humans (for recent reviews, see Carter and Griffiths 2009; O'Connor et al. 2011) , and the effects of D 2 -like agonists in patient populations.
In an attempt to elucidate the variables involved in the maintenance of self-administration behavior by D 2 -like agonists in rats, we have previously evaluated the influence of reinforcement history, operant history, and conditioned stimuli on the capacity of quinpirole to maintain responding. In rats, quinpirole maintained high rates of responding when substituted for cocaine or remifentanil, but failed to maintain responding in experimentally naïve rats, or rats with histories of either ketamine or food reinforcement , suggesting that a relatively specific drug reinforcement history is necessary to establish the reinforcing effects of D 2 -like agonists. However, that quinpirole also failed to maintain responding in cocainetrained rats when substituted on a previously unreinforced manipulandum, or when quinpirole injections were delivered without the previously cocaine paired stimuli suggests that simply providing an appropriate reinforcement history is not sufficient to establish the reinforcing effects of D 2 -like agonists . When taken together with the finding that experimenter-administered quinpirole was equally effective at producing high rates of responding when responses resulted in the presentation of the cocaine-paired stimuli alone (i.e., no cocaine injection), these studies suggest that the response-maintaining effects of quinpirole are primarily mediated by an interaction between the activation of D 2 and/or D 3 receptors and the previously cocaine-paired stimuli, rather than a reinforcing effect of the quinpirole injection itself.
Although D 2 -like agonists do not appear to function as reinforcers in humans, they are known to induce a variety of compulsive behaviors, with an estimated 14% of patients who take these drugs displaying some form of an impulse control disorder (ICD) (Voon and Fox 2007; Weintraub et al. 2010) . Originally described in Parkinson's patients as a pramipexole-induced increase in the occurrence of pathological gambling (Driver-Dunckley et al. 2003) , subsequent reports of compulsive eating, shopping, and sexual behavior in Parkinson's, restless-leg, and fibromyalgia patients being treated with pramipexole or ropinirole (e.g., DriverDunckley et al. 2007; Holman 2009; Voon et al. 2006; Weintraub 2008) suggest that the pathophsyiologic changes associated with Parkinson's are not necessary for the manifestation of ICDs. Although the mechanisms responsible for the development and maintenance of ICDs are currently unknown, it is important to note that these problematic behaviors typically resolve following dose reduction or cessation of treatment, indicating that D 2 -like agonists play a causal role in the expression of these compulsive behaviors.
The present studies were aimed at evaluating the capacity of the D 3 -preferring agonist pramipexole (~30-fold selective for D 3 over D 2 in vivo; ; and~90-fold selective for D 3 over D 2 in vitro; Millan et al. 2002) to maintain responding when substituted for cocaine, and to enhance responding for the stimuli that were previously paired with cocaine reinforcement (CS). First, the capacities of response-contingent pramipexole to maintain responding, and non-contingent pramipexole to induce responding were evaluated in cocaine-trained rats. Second, in order to determine whether pramipexole-induced responding represents an increase in the reinforcing effectiveness of the CS, pramipexole was administered prior to sessions in which rats were allowed to respond for CS presentation under a progressive ratio (PR) schedule of reinforcement. Third, since the CS was comprised of multiple components including a yellow light that served as the discriminative stimulus and signaled drug availability (CS D ), as well as a 0.5-s illumination of a green light followed by a 5-s illumination of the houselight that was paired with cocaine reinforcement (CS R ), the relative importance of the CS D and CS R on the capacity of pramipexole to induce PR responding were systematically evaluated. Finally, D 3 -and D 2 -preferring antagonists were used to assess the relative contributions of the D 3 and D 2 receptors to pramipexole's effects on CS-maintained responding.
Methods

Subjects
Male Sprague-Dawley rats (250-300 g) were obtained from Harlan (Indianapolis, IN), and individually housed for the duration of the study in a temperature-(21-23°C) and humidity-controlled environment, on a 12-h dark/light cycle with lights on at 7:00 AM. Rats had free access to tap water and~20 g of Purina rat chow per day to maintaiñ 80% of their free feeding weight. All studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Research 1996), as adopted and promulgated by the National Institutes of Health, and all experimental procedures were approved by the University of Michigan Committee on the Use and Care of Animals.
Surgery
Rats were surgically prepared with a chronic indwelling catheter in the left femoral vein under ketamine/xylazine (90:10 mg/kg, IP) anesthesia. Catheters were passed under the skin and attached to stainless steel tubing, exiting the back through a metal tether button positioned between the scapula. Rats were allowed 5-7 days to recover, and catheters were flushed with 0.2 ml of heparinized saline (100 U/ml) during recovery, as well as before and after sessions to ensure patency.
Apparatus and stimuli conditions
All experimental sessions were conducted in operant conditioning chambers (30.5×24×21 cm [W×D×H] ; Med Associates Inc., St. Albans, VT) placed inside sound attenuating cubicles. Each chamber was equipped with a nosepoke aperture located 6 cm above the grid floor and 1.5 cm from the left side of the wall, and a lever located 6.8 cm above the grid floor and 1.3 cm from the right side of the same wall (ENV-110M, ENV-114BM; Med Associates). A white houselight (4.23 lx as measured from center of chamber) was located at the top center of the opposite wall. A yellow light inside the nosepoke aperture (0.11 lx as measured from center of chamber), and a set of green, yellow, and red LED lights (green, 0.11 lx; yellow, 0.17 lx; red, 0.05 lx; green, yellow and red, 0.33 lx as measured from center of chamber) above both the nosepoke aperture and lever could be illuminated. As summarized in Table 1 , Illumination of the yellow light inside the nosepoke aperture served as the discriminative stimulus (CS D ), whereas the 0.5-s illumination of the green LED above the nosepoke aperture followed by the 5-s illumination of the houselight served as the injection paired stimuli (CS R ), and the 0.5-s illumination of the three LEDs above the lever followed by a 5-s period in which the houselight flashed at 0.5 Hz (1 s on, 1 s off) served as the novel stimuli (NvlS). The NvlS was included to control for non-specific effects of pramipexole on stimuli that had not been conditioned to cocaine, and the lever response was used so that the rats would have to make a topographically different response for the NvlS, thus reducing the possibility that they would make a cocaine-appropriate response (i.e., a nosepoke). Drug solutions were delivered by a pneumatic syringe pump (IITC, Woodland Hills, CA) through Tygon® tubing connected to a stainless steel fluid swivel (Instech Laboratories, Plymouth Meeting, PA) and spring tether which was held in place by a counterbalanced arm.
Fixed ratio: training procedures
Prior to experimental manipulations, seven groups of rats (n=6/group) were trained to nosepoke for 0.56 mg kg −1 inj cocaine −1 under a fixed ratio (FR) 1 timeout (TO) 5.5-s schedule of reinforcement during daily 90-min sessions. This dose of cocaine was chosen based on previous experience suggesting that a high percentage of rats would acquire responding, and to allow for a historical comparison between the effects of pramipexole and quinpirole Woods 2007, 2009 
, and ratio completion resulted in an injection (100 μl/kg/0.5 s) paired with a 0.5-s illumination of a green LED located above the nosepoke aperture, and followed by a 5-s illumination of the houselight (CS R ). During this 5.5-s period, all other stimuli were extinguished, and responding was recorded but had no scheduled consequence. Although lever presses were recorded they had no scheduled consequence. Upon acquisition of stable responding, defined as three consecutive sessions with less than a 20% difference, and no increasing or decreasing trend in responding, rats were randomly assigned to either substitution (six groups of six), or pretreatment studies (one group of six).
Stimulus Conditions
CS
Yellow LED inside nosepoke aperture 0.5-s Green LED above nosepoke aperture followed by 5-s illumination of houselight CS D Yellow LED inside nosepoke aperture CS R 0.5-s Green LED above nosepoke aperture followed by 5-s illumination of houselight NvlS 0.5-s Green, Yellow, and Red LED above lever followed by 5-s flashing of houselight at 0.5 Hz R ) associated with the nosepoke aperture were identical to the training conditions, a yellow LED above the lever was now illuminated concurrent with the CS D to signal that the lever was active, and that presses now resulted in a novel set of stimuli (NvlS) consisting of a 0.5-s illumination of three LEDs above the lever and a 5-s flashing (0.5 Hz) of the houselight, but no injection. Substitutions were carried out for seven consecutive sessions, after which the original contingencies (i.e., nosepoke for 0.56 mg kg −1 inj cocaine −1 under a FR1TO5.5 s) were in place for 5 days.
The influence of the CS on nosepoke responding for pramipexole (0.1 mg kg −1 inj −1 ) was evaluated in a separate group of six cocaine-trained rats, with substitutions conducted in three phases over 13 consecutive, 90-min sessions under a concurrent FR1TO5.5-s:FR1TO5.5-s schedule of reinforcement. The first phase of the substitution lasted three sessions, and was identical to the substitution studies above (i.e., CSs and pramipexole injections were scheduled on the nosepoke aperture, and NvlSs were scheduled on the lever). The second phase of the substitution lasted seven sessions, with nosepoke and lever responses reinforced under a concurrent FR1TO5.5-s:FR1TO5.5-s schedule of reinforcement. During this phase, CSs and NvlSs were removed from the contingencies and nosepoke responses resulted in 0.1 mg kg −1 inj pramipexole −1 followed by an un-signaled 5.5-s TO, and lever presses resulted in an unsignaled 5.5-s TO. The CSs and NvlSs were reintroduced on the nosepoke and lever, respectively, during the third phase of the substitution, which lasted three sessions and was run under conditions identical to those described for the first phase of the substitution.
Fixed ratio: pretreatment studies
To assess the direct effects of pramipexole on responding, a separate group of six cocaine-trained rats were pretreated with saline, or one of four doses of pramipexole (0.032, 0.1, 0.32, and 1.0 mg/kg; SC) immediately prior to the start of 90-min sessions in which nosepoking and lever pressing were reinforced under a concurrent FR1TO5.5-s: FR1TO5.5-s schedule of reinforcement. The stimuli conditions were identical to those described for the substitution sessions above (i.e., the CS D and yellow light above the lever signaled the active portion of the session, and the CS R and NvlS were presented upon ratio completion on the nosepoke and lever, respectively). However, unlike during the substitution studies no injections could be earned. Pramipexole doses were selected based on evidence that suggests the lower two doses (0.032 and 0.1) preferentially activate D 3 receptors, whereas the higher two doses activate both D 3 and D 2 receptors in rats (Collins et al. 2005 ). Doses were presented in random order, with each rat receiving each dose for three consecutive sessions.
Upon completion of the dose response, rats were pretreated with 0.32 mg/kg pramipexole for six additional sessions to test the importance of the CS on nosepoking, and the NvlS on lever pressing. Three of these sessions were conducted using stimulus conditions that were identical to those described above, however, all CSs and NvlSs were omitted from the contingencies during the other three sessions so that responses on the nosepoke or lever resulted in an un-signaled 5.5-s TO. Each condition was in place for three consecutive sessions, with the order of the conditions counterbalanced across rats.
Progressive ratio: training procedures Two additional groups of six rats were trained to nosepoke for 0.56 mg kg −1 inj cocaine −1 under the identical FR1TO5.5-s schedule of reinforcement used for the FR studies with the exception that the ratio requirements were gradually increased until responding stabilized at FR10. Rats were subsequently switched to a progressive ratio (PR) schedule of reinforcement, under which ratios incremented exponentially (1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 145, 178, 219, 268, 328, 402, 492, 603, 737, 901, 1,102, etc.) ]−5) from Richardson and Roberts (1996) . Sessions lasted a maximum of 4 h, but terminated if a ratio was not completed within 45 min (i.e., 45-min limited hold). Upon stabilization of responding, defined as at least seven sessions with less than a 20% difference and no increasing or decreasing trend in the number of ratios completed, rats were randomly assigned to either conditioned stimuli (one group of six), or antagonist studies (one group of six).
Progressive ratio: dose-response analysis and conditioned stimuli studies Pretreatments with saline and each of four doses of pramipexole (0.032, 0.1, 0.32, and 1.0 mg/kg, SC) occurred immediately prior to sessions in which the CS D signaled the active portion of the session, and ratio completion resulted in presentation of the CS R , but no longer resulted in cocaine injections. All five dosing conditions were evaluated in each rat, with the first dose always being 0.32 mg/kg pramipexole, and the remaining doses were presented in random order. Each dose was administered for at least three consecutive sessions. Progressive ratio: antagonist studies As described above, saline or pramipexole (0.1, 0.32, 1.0, and 3.2 mg/kg, SC) was administered immediately before sessions in which the CS D signaled the active portion of the session and ratio completion resulted CS R presentation, but no longer resulted in cocaine injections. All five dosing conditions were evaluated in each of the six rats, with the 0.32 mg/kg dose always assessed first, and the remaining doses evaluated in random order. Each dose of pramipexole was administered for at least three consecutive sessions prior to assessing a 1.0 mg/kg dose of the D 2 -preferring antagonist L-741,626 (~13-fold selective for D 2 over D 3 receptors in vitro; Millan et al. 2000) , and a 32.0 mg/kg dose of the D 3 -preferring antagonist PG01037 (~133-fold selective for D 3 over D 2 receptors in vitro; Grundt et al. 2005 Grundt et al. , 2007 . Antagonists were administered as 30-min pretreatments to pramipexole, with the doses chosen based on their capacity to selectivity antagonize in vivo effects that have been linked to the activation of D 2 (hypothermia) or D 3 (yawning) receptors (Collins et al. 2005 ). The order of antagonist administration was randomized across rats, and separated by least three sessions.
Upon completion of all antagonist × pramipexole dosing combinations, the dose-response curve for pramipexole alone (saline, 0.1, 0.32, 1.0, and 3.2 mg/kg, SC) was reevaluated prior to assessing the effects of cocaine (3.2, 10.0, and 32.0 mg/kg, IP) on PR responding for the CS. The doses of pramipexole and cocaine were administered for at least three consecutive sessions, and were presented in random order.
Drugs
Cocaine was obtained from the National Institute on Drug Abuse (Bethesda, MD). PG01037 was synthesized by Ms. J. Cao (Medicinal Chemistry Section-NIDA, Baltimore, MD) according to published procedures . Pramipexole was obtained from APAC Pharmaceutical (Columbia, MD), and L-741,626 was obtained from Tocris Chemical (Ellisville, MO). Cocaine and pramipexole were dissolved in physiologic saline. L-741,626 was dissolved in 5% ethanol and sterile water, and PG01037 was dissolved in 10% β-cyclodextrin. All pretreatments were administered subcutaneously in a volume of 1.0 ml/kg.
Data analysis
All data are presented as the mean ± SEM, n=6, for each endpoint. Significant differences in responding during pramipexole substitutions were determined using two-way (Dose × Session) repeated measures analysis of variance (ANOVA) with post-hoc Bonferroni tests (GraphPad Prism). Significant effects of CS presentation on pramipexole-maintained responding were determined using one-way (Session) repeated measures ANOVA with posthoc Newman-Keuls. Significant effects of CS on pramipexole-induced FR1 responding were determined by two-tailed paired t-tests. Significant effects of pramipexole or cocaine pretreatment on responding (and other PR endpoints) were determined using a one-way (Dose) repeated measures ANOVA with post-hoc Newman-Keuls tests and compared the respective endpoints observed during cocaine-maintained responding, or following saline pretreatments. A two-way (Antagonist Dose × Pramipexole Dose) repeated measures ANOVA with post-hoc Bonferroni tests was used to determine if antagonists significantly altered the effects of pramipexole on PR endpoints, as well as to determine if the effects of pramipexole on PR responding were significantly altered upon reevaluation (Time × Pramipexole Dose).
Results
Fixed ratio: substitution studies
As shown in Fig. 1 , pramipexole maintained FR1TO5.5-s responding in a dose-and session-dependent manner when substituted for 0.56 mg kg −1 inj cocaine −1 (Dose: F 4,150 =9.7;
p<0.001; Session: F 6,150 =6.0; p<0.001). High rates of responding were maintained by doses of 0.032 to 0.32 mg kg −1 inj pramipexole −1 over the last 6 days of the substitution, with a dose of 0.1 mg kg −1 inj −1 maintaining significantly more responding than saline on each of the last 6 days ( Fig. 1, top panel) , and doses of 0.032, and 0.1 mg kg −1 inj pramipexole −1 maintaining significantly more responding than saline on day 7 (Fig. 1, middle panel) . Although slight increases in lever responding were observed following the introduction of the NvlS contingency, lever pressing during pramipexole substitutions was no different (Dose: F 4,150 =0.6; p=0.66; Session: F 6,150 =1.4; p=0.2) than when saline was available for injection (data not shown). These high rates of pramipexole-maintained responding were dependent upon the injection-CS pairing (F 10,50 =20.1; p< 0.001) as significantly lower rates of nosepoking were observed throughout the 7-day period when CS (i.e., CS D and CS R ) presentations were omitted (Fig. 1, bottom  panel) . Following the reintroduction of the injection-CS pairing, nosepoking occurred at rates that were no different than those observed prior to removal of the CS from the contingency. Although removal of the NvlS contingency from the lever did not significantly alter rates of lever pressing, a slight but significant increase lever pressing was observed when the rats were returned to the original substitution contingencies in which nosepoking resulted in pramipexole paired with the CS, and lever pressing resulted in the presentation of the NvlS (Fig. 1,  bottom 
panel).
Fixed ratio: pretreatment studies Dose-dependent (F 4,15 =6.9; p<0.01) increases in nosepoke responding were also observed when rats were pretreated with pramipexole prior to sessions in which nosepoke responses resulted in CS presentation and lever presses resulted in NvlS presentation (Fig. 2) . Although significant increases in nosepoke responding were observed following pretreatment with doses of 0.32 and 1.0 mg/kg pramipexole, no increases in lever pressing were observed following administration of any dose of pramipexole. In addition, these pramipexole-induced increases in nosepoke responding were dependent upon the nosepoke-CS contingency as responding occurred at significantly lower, saline-like rates when CS presentations were omitted (p <0.05). ). **p<0.01; ***p<0.001. Significant differences in nosepoke responding from saline were determined by one-way ANOVA with post-hoc Newman-Keuls tests. . Filled symbols represent nosepoke responses (filled circles) that resulted in the delivery of pramipexole in conjunction with presentation of the CS and lever presses (filled squares) that resulted in presentation of the NvlS. Open symbols represent nosepoke responses (open circles) that resulted in the delivery of pramipexole and an un-signaled 5.5-s TO, and lever presses (open squares) that resulted in an un-signaled 5.5-s TO. **p<0.01; ***p<0.001; ++ p<0.01; +++ p<0.001. Significant differences in nosepoke (*) or lever (+) responding as compared with nosepoke or lever responding during day 3 of the substitution were determined by one-way ANOVA with post-hoc Newman-Keuls tests Progressive ratio: conditioned stimuli studies Similar to the effects observed when pramipexole was administered prior to sessions in which CSs were presented for nosepoking on an FR1TO5.5-s schedule of reinforcement, dose-dependent increases (F 4,20 =46.1; p<0.001) in CS-maintained responding were also observed when pramipexole was administered prior to sessions in which CS presentations were delivered under a PR schedule of reinforcement. As shown in Fig. 3 , pretreatment with doses of 0.32 and 1.0 mg/kg pramipexole resulted in significantly more responding than was observed after saline pretreatment or during cocaine reinforced sessions. Pramipexole did not alter lever (inactive) responding at any dose tested. Pramipexole pretreatments also resulted in dose-dependent increases in the number of CS presentations earned (F 4,20 = 55.3; p<0.001), final ratio completed (F 4,20 =38.5; p< 0.001), response rates (F 4,20 =53.2; p<0.001), and total session duration (F 4,20 =29.2; p<0.001) as compared with when saline was administered prior to the session.
As was observed with FR1 responding for CS presentation, altering the stimulus conditions significantly affected the capacity of pramipexole to induce responding under a PR schedule of reinforcement (F 3,15 =14.2; p< 0.001). As shown in Fig. 4 , significantly lower levels of responding were observed when 0.32 mg/kg pramipexole was administered prior to sessions in which the CS D and CS R were omitted from the contingency, as well as when the CS D was scheduled, but ratio completion failed to produce CS R presentation. Conversely, when the CS D was not presented, but ratio completion resulted in CS R presentation, responding occurred at levels no different than those observed in the CS D -CS R condition. Altering the stimulus conditions also significantly reduced the number of ratios completed (F 3,15 =27.5; p<0.001), final ratio completed (F 3,15 =10.6; p <0.001), and response rates (F 3,15 =16.4; p<0.001) However, the total session duration Fig. 3 Effects of pretreatment with saline or pramipexole (0.032, 0.1, 0.32, and 1.0 mg/kg, SC) prior to sessions in which nosepoke responding was reinforced under a progressive ratio (PR) schedule of reinforcement by presentation of the previously cocaine-paired stimuli (CS). Black symbols represent the mean ± SEM, n=6, of each endpoint during the last day of PR responding for 0.56 mg kg −1 inj cocaine −1 for each endpoint. The total number of CS-reinforced nosepoke responses (gray circles) and inactive lever responses (open squares) are shown on the left y-axis, and represent the mean ± SEM, n=6, number of responses emitted during the final session for each pretreatment dose. The final ratio completed (open triangles) are shown on the right y-axis, and represent the mean ± SEM, n=6, value of the final ratio that was completed prior to session termination due to the 45-min limited hold, or 240-min session limit, whichever came first.
+++ p < 0.001; ***p < 0.001. Significant differences in each endpoint compared to saline pretreatment (*) or 0.56 mg kg −1 inj cocaine −1 -reinforced responding (+) were determined by one-way repeated measures ANOVA with post-hoc Newman-Keuls tests + p<0.05. Significant differences between the amounts of responding observed during sessions in which nosepoke and lever responding resulted in the presentation of the CS and NvlS, and sessions in which CS and NvlS presentations were omitted were determined by two-tailed t-tests was unaffected by manipulation of the stimulus conditions, with all sessions lasting approximately 230 min.
Progressive ratio: antagonist studies As shown in Fig. 5 , pramipexole induced dose-dependent increases in CS-maintained responding (F 4,20 =25.0; p< 0.001) and final ratio completed (F 4,20 =24.0; p<0.001) over a wide range of doses with significant increases observed following doses of 0.32, 1.0, and 3.2 mg/kg pramipexole. Similar dose-dependent increases were also observed with respect to the number of ratios completed, response rate, and session duration (data not shown). Pretreatment with a D 2 dose of 1.0 mg/kg L-741,626 produced a significant rightward shift in the dose-response curve, with significantly lower levels of responding (F 1,25 = 17.5; p<0.001) and final ratio completed (F 1,25 =17.0; p< 0.001) observed at the 1.0 mg/kg L-741,626 ×0.32 mg/kg pramipexole dose combination. Unlike the effects of L-741,626 , pretreatment with a D 3 dose of 32.0 mg/kg PG01037 produced a downward shift in dose-response curve for pramipexole-induced responding (F 1,25 =7.8; p<0.01) and the final ratio completed (F 1,25 =7.4; p<0.05), with significant reductions in responding and the final ratio completed observed at the 3.2 mg/kg dose of pramipexole (Fig. 5) . Table 2 shows the effects of pretreatment with pramipexole or cocaine on PR responding for CS presentation. Pramipexole induced dose-dependent increases in nosepoke responding (F 5,20 =18.1; p<0.001), final ratio (F 5,20 =18.7; p<0.001), CSs earned (F 5,20 =82.7; p<0.001), response rate (F 5,20 = 11.1; p<0.001), and session duration (F 5,20 =41.9; p<0.001) when PR responding resulted in CS presentation, and there were no significant differences between the initial dose response and the subsequent redetermination of pramipexoleinduced PR responding for CS presentation obtained approximately 45 to 60 sessions after the termination of cocaine self-administration. Although cocaine produced dose-dependent increases in nosepoke responding (F 3,15 = Fig. 5 Effects of the pretreatment with the D2-preferring antagonist L-741,626 (1.0 mg/kg, SC), or the D3-selective antagonist PG01037 (32.0 mg/kg, SC) on the response-inducing effects of pramipexole (0.1, 0.32, 1.0, and 3.2 mg/kg, SC) or saline. Data represent the final ratio completed during sessions in which nosepoke responding was reinforced under a progressive ratio (PR) schedule of reinforcement by presentation of the stimuli that were previously paired with 0.56 mg kg −1 inj cocaine −1 reinforcement (CS). Saline data (gray circles) represent the mean ± SEM, n=6, of final ratios completed for sessions in which saline was administered 30 min prior to the administration of pramipexole (or saline). The effects of 1.0 g/kg L-741,626 (open inverted triangles) and 32.0 mg/kg PG01037 (open diamonds) represent the mean ± SEM, n=6, final ratio completed during sessions in which antagonists were administered 30 min prior to the administration of pramipexole (or saline). *p<0.05; ***p<0.001. Significant differences in the final ratio completed during sessions that were preceded by antagonist pretreatment as compared to those that were preceded by saline were determined by two-way repeated measures ANOVA with post-hoc Bonferroni tests , nor the CS R were scheduled; CS D only the CS D was scheduled; CS R only the CS R was scheduled. Data represent the mean ± SEM, n=6, for each endpoint during the final session that each condition was in place. Total nosepoke responses (black bars) are shown on the left y-axis and represent the mean ± SEM, n=6, number of nosepoke responses that resulted in ratio completion. The final ratio completed (gray bars) is shown on the right y-axis and represent the mean ± SEM, n=6, value of the final ratio that was completed prior to session termination due to the 45-min limited hold, or 240-min session limit, whichever came first. The session duration (open bars) is shown on the right y-axis and represents the mean ± SEM, n=6, time in minutes that elapsed prior to session termination due to the 45-min limited hold, or 240-min session limit, whichever came first. **p<0.01; ***p<0.001; ++ p<0.01; +++ p<0.001. Significant differences from CS R -CS D (*) and No Stim (+) as determined by one-way repeated measures ANOVA with post-hoc Newman-Keuls tests 4.7; p<0.05), final ratio completed (F 3,15 =4.6; p<0.05), CSs earned (F 3,15 =7.3; p<0.01), response rate (F 3,15 =3.6; p< 0.05), and session duration (F 3,15 =3.8; p<0.05) when administered prior to sessions in which nosepoke responses resulted in CS presentation these effects were much smaller in magnitude than those observed following pretreatment with pramipexole.
Discussion
Previous studies have demonstrated that the responsemaintaining effects quinpirole, a D 3 -preferring agonist, appear to be dependent upon relatively specific reinforcement histories, as well as an interaction between quinpirole and the stimuli that were previously paired with cocaine reinforcement Woods 2007, 2009 ). The results of the current studies confirm these general findings and extend them in several ways. First, when substituted for cocaine, the clinically used D 3 -preferring agonist pramipexole maintained responding in a dose-dependent and selective manner, with high rates of responding observed when pramipexole injections were paired with stimuli that were previously paired with cocaine reinforcement (i.e., the CS), and significantly lower rates of responding observed when CS presentation was omitted. Second, dosedependent and selective increases in nosepoke responding were also observed when cocaine-trained rats were pretreated with pramipexole and allowed to respond under an FR1 for CS presentation alone, with peak rates of responding similar to those observed when pramipexole injections were paired with the CS and delivered contingent upon responding. Third, pramipexole induced dosedependent and selective increases in nosepoke responding when CSs were presented under a PR schedule of reinforcement, with maximal increases in responding approximately 10 times greater than those produced by pretreatment with cocaine. Fourth, these large increases in responding were dependent upon an interaction between pramipexole and the stimuli that were previously paired with cocaine injections (CS R ), rather than those that predicted cocaine availability (CS D ). Finally, D 2 and D 3 antagonists differentially affected pramipexole-induced PR responding for CS presentation, with the D 2 -preferring antagonist L-741,626 producing a rightward shift, and the D 3 -preferring antagonist PG01037 producing a downward shift in the dose-response curve. Together, these studies suggest that although pramipexole injections are capable of maintaining responding when substituted for cocaine, the high rates of responding are being controlled by the contingency between the response and the CS presentation rather than by the injection of pramipexole itself.
Similar to previous reports with quinpirole , the capacity of pramipexole injections to maintain responding appeared to be dependent upon their being paired with the CS, as these high rates of pramipexole-maintained responding were not only significantly reduced when the CS was removed from the contingency, but also recovered following the reintroduction of the injection-CS pairing. Importantly, a previous study failed to show similar decreases in FR1 responding maintained by 0.56 mg kg −1 inj cocaine −1 following removal of the CS from the contingency , suggesting that CS presentations may be more important for drugs that function as weak reinforcers, such as nicotine (Donny et al. 2003) , or when low doses of drugs that are typically thought of as powerful reinforcers, such as cocaine, are available for injection (Schenk and Partridge 2001) . In addition to enhancing pramipexole's response-maintaining effects, the CS was also important for pramipexole's response-inducing effects. Not only were the dose-dependent increases in responding produced by experimenter-administered pramipexole selective for conditions in which nosepoke responses were reinforced by the CS, but they also occurred in the absence of any increase in lever responding which resulted in a similar, but novel stimulus change (NvlS), and at doses that lack locomotor stimulatory effects (Collins et al. 2011) . Together, these findings suggest that the response-maintaining and response-inducing effects of pramipexole are similarly mediated by an interaction between the direct effects of pramipexole and the conditioned effects of the CS, rather than a more general increase in responding for neutral stimuli (i.e., NvlS) as has been shown for other drugs, such as nicotine (Donny et al. 2003) .
Although the effects of pramipexole on responding maintained by conditioned stimuli have not been studied in rats, quinpirole has been shown to dose-dependently increase responding for stimuli previously paired with water (Wolterink et al. 1993) , or cocaine , suggesting that D 2 -like agonists may be psychostimulant-like in their capacity to enhance the reinforcing effects of conditioned stimuli (e.g., Beninger et al. 1981; Robbins 1976 Robbins , 1978 Robbins and Koob 1978) . Consistent with this notion, experimenter-administered pramipexole also produced dose-dependent increases in responding when CSs were available under a PR schedule of reinforcement which is commonly used to assess the relative reinforcing effectiveness of drug and non-drug reinforcers. Importantly, even though rats earned approximately 8 times fewer CS presentations, they emitted 10 times more responses, and responded 4 times faster when pramipexole was administered prior to PR as compared to FR1 sessions, suggesting that pramipexole-induced, CSmaintained responding was occurring in a schedule appropriate manner. Moreover, these effects of pramipexole were not only persistent, lasting for at least 60 sessions, but the high rates of responding corresponded to CSs maintaining substantially higher final ratios (greater than 300) than when either cocaine (~37), or saline (~7) was administered prior to the session.
Whilst these findings suggest that CSs were functioning as powerful reinforcers when rats were under the influence of pramipexole, it should be noted that D 2 -like agonists, such as quinpirole, have also been shown to induce perseverative responding in a variety of operant procedures (Boulougouris et al. 2009; Joel et al. 2001; Kurylo 2004; Kurylo and Tanguay 2003) , raising the possibility that these increases in responding were mediated by a mechanism(s) distinct from alterations in the reinforcing effectiveness of the CS. To this end, the effectiveness of pramipexole to induce PR responding was evaluated under a variety different stimulus conditions. In agreement with a pramipexole-induced enhancement of conditioned reinforcement, the stimuli that were previously paired with cocaine injection (CS R ) maintained equally high rates of responding regardless of whether the stimulus that predicted cocaine availability (CS D ) was scheduled or not. Curiously, although removal of either the CS R alone, or both the CS R and the CS D resulted in significantly lower levels of responding, pretreatment with pramipexole continued to induce low rates of responding that were sufficient to extend the sessions for approximately 230 min despite the fact that there was no scheduled consequence for responding. Given than pretreatments with saline or low doses of pramipexole resulted in low levels of responding over relatively short periods of time (~50-95 min), these findings suggest that pramipexole's main effect may have been to induce low levels of perseverative, unreinforced responding, with high rates of responding only observed when responses resulted in the presentation of the CS R . Alternatively, since D 2 -like agonists are known to possess cocaine-like discriminative stimulus effects (e.g., Barrett et al. 2001; Terry et al. 1994) , it is possible that increases in nosepoke responding (i.e., cocaine-appropriate responding) resulted from a cocaine-like enteroceptive stimulus produced by pramipexole that "suggested" cocaine availability. Although the current data suggest that any potential overlap between the enteroceptive effects of pramipexole and cocaine were insufficient to produce high rates of responding in the absence of the CS , R this is nonetheless an intriguing possibility that warrants further study to more fully elucidate the degree to which the enteroceptive effects of pramipexole are involved in its response-maintaining and response-inducing effects.
Although the doses of pramipexole that were active in the current studies are known to have effects at both D 3 and D 2 receptors in rats (Collins et al. 2005 (Collins et al. , 2008 , the parallel rightward shift of the dose-response curve for pramipexole-induced, CS-maintained responding produced by the D 2 -preferring antagonist L-741,626 suggests that these effects are mediated by an agonist activity at the D 2 receptor. While the lack of D 2 -like agonist selfadministration in D 2 receptor knockout mice (Caine et al. 2002) supports this notion, the downward shift in the doseresponse curve produced by the D 3 antagonist PG01037 raises the possibility that these effects are also modulated by D 3 receptor activation. That PG01037 was not more effective at altering CS-maintained responding was somewhat surprising given reports that D 3 antagonists effectively inhibit responding that is either induced (e.g., cue-induced reinstatement) or maintained (e.g., second-order schedules of reinforcement) by stimuli conditioned to a variety of drug reinforcers (e.g., Cervo et al. 2007; Di Ciano et al. 2003; Higley et al. 2010; Khaled et al. 2009; Pilla et al. 1999) . However, since similar studies have not been performed with antagonists that possess even modest degrees of selectivity for the D 2 receptor, such as L-741,626, it is difficult to determine the relative contributions of these two receptor subtypes in other cue-related behaviors. In addition, although the relative ineffectiveness of PG01037 may be due to a prepotent stimulation of D 2 receptors by pramipexole that does not occur in cueinduced reinstatement experiments, reports that PG01037 equipotently decreases PR responding for methamphetamine and sucrose (Higley et al. 2010 ) raise the possibility that the current decreases in PR responding may have resulted from a non-specific effect of PG01037 on relatively high rates of responding.
In summary, the results of these studies provide convergent evidence to suggest that the CS R was capable of functioning as a powerful reinforcer in its own right when rats were under the influence of pramipexole. Importantly, these pramipexole-induced increases in CS-maintained responding were not only dose-dependent and sensitive to changes in the stimulus condition; they were also blocked by L-741,626, suggesting that they are primarily mediated by a D 2 receptor mechanism. Moreover, when taken together with the capacity of pramipexole to induce persistent, low rates of unreinforced responding these results suggest that pramipexole's primary effect may be to induce low levels of perseverative, or "habitual" responding, with high rates of responding only occurring in situations in which pramipexole-treated rats come into contact stimuli that have taken on conditioned reinforcing properties.
Interestingly, these effects appear to be similar to those observed in a subset of patients being treated with dopamine replacement therapies (e.g., L-DOPA, pramipexole, and ropinirole). In addition to an increased occurrence of ICDS (Driver-Dunckley et al. 2003 Holman 2009; Weintraub et al. 2010; Weintraub and Potenza 2006) , these drugs have also been associated with the development of punding (Evans et al. 2004; ). Although ICDs involve increases in goal-oriented behaviors (e.g., gambling, eating, shopping, and sex), whereas punding involves prolonged, stereotyped patterns of behavior that are habitual in nature and often related to the patients' occupations, hobbies, or pastimes, both of these effects are typically described as compulsive in nature, and are likely influenced to a great degree by an individual's history, and/or the environmental stimuli that have been associated with the particular activity. Furthermore, just as the pramipexole-induced increases in responding described in the current studies were highly dosedependent, these aberrant behaviors are more common in patients taking high doses of D2-like agonists, and generally resolve upon dose reduction, or the cessation of treatment (e.g., Evans et al. 2004; Weintraub 2008) . Finally, although the current studies were limited to studying the effects of pramipexole in animals that were trained to respond for cocaine, there is evidence to suggest that this may be a more general effect of D 2 -like agonists to enhance conditioned reinforcing effects as similar increases in responding have also been observed for water-paired stimuli (Wolterink et al. 1993) . Nevertheless, the degree to which the observed effects were influenced by the overlapping enteroceptive effects of pramipexole and cocaine and/or the specific reinforcement history is not known. Further studies will be required to more fully examine the generality of pramipexole's conditioned reinforcement enhancing effects, as well as how these effects may relate to clinical observations of pramipexole-induced ICDs specifically, and drug abuse-related behaviors more generally.
